002332 仙琚制药
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入2,928,3733.64%3,758,9694,000,6934,123,4194,379,826
减:营业总成本2,470,1763.71%3,292,1973,310,4863,489,8783,643,766
    其中:营业成本1,120,1275.18%1,458,9681,700,8431,943,1241,832,759
               财务费用7,335-239.46%(7,849)(34,282)(22,317)(26,711)
               资产减值损失(31,679)30.81%(38,214)(43,510)(28,557)(32,163)
公允价值变动收益------------
投资收益(14,546)18.74%(26,411)(8,136)(8,974)49,354
    其中:对联营企业和合营企业的投资收益(14,423)19.56%(26,942)(21,763)(7,953)(3,873)
营业利润434,368-6.41%472,358678,211646,459878,597
利润总额504,40710.29%535,841498,327641,681871,892
减:所得税费用85,74139.46%83,23798,40479,562124,494
净利润418,6665.76%452,604399,923562,118747,397
减:非控股权益(3,549)-67.18%2,9632,744(965)(2,014)
股东净利润422,2153.82%449,640397,179563,083749,411

市场价值指针
每股收益 (元) *0.4294.26%0.4500.4000.5700.758
每股派息 (元) *0.1000.00%0.3000.3000.3000.300
每股净资产 (元) *5.964-1.55%6.1015.9075.8495.517
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容